Periotherapia Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $6.82M

  • Investors
  • 9

Periotherapia General Information

Description

Developer of antibody therapies designed to target pathological periostin for intractable diseases. The company offers pathological periostin neutralizing antibodies, metastatic breast cancer therapies, recurrent breast cancer treatments, diagnostic agents, antibody drug candidates, and clinical trial pharmaceuticals, enabling medical institutions to treat resistant cancers and inflammatory diseases through selective splicing variant targeting and academic research integration.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2-12-11 Nishinakajima
  • Yodogawa-ku
  • Osaka, 532-0011
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2-12-11 Nishinakajima
  • Yodogawa-ku
  • Osaka, 532-0011
  • Japan

Periotherapia Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Periotherapia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 02-Jun-2026 $6.82M Completed Generating Revenue
7. Later Stage VC (Series D2) 26-May-2026 Completed Generating Revenue
6. Later Stage VC (Series D) 31-Jan-2025 Completed Generating Revenue
5. Later Stage VC (Series C) 09-Mar-2022 Completed Generating Revenue
4. Early Stage VC (Series B) 01-Sep-2020 Completed Generating Revenue
3. Early Stage VC (Series A) 05-Apr-2019 Completed Generating Revenue
2. Seed Round 13-Dec-2017 $622K $622K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Periotherapia’s complete valuation and funding history, request access »

Periotherapia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class D
Class D1
Class C1
Series C
Series B
Series A 3,572 $446.76 $446.76 1x $446.76 12.52%
Series A-1 2,000 $223.38 $223.38 1x $223.38 7.01%
To view Periotherapia’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Periotherapia Patents

Periotherapia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022406341-A1 Antibody or antigen-binding fragment thereof Pending 07-Dec-2021
CA-3242041-A1 Antibody or antigen-binding fragment thereof Pending 07-Dec-2021
EP-4446343-A1 Antibody or antigen-binding fragment thereof Pending 07-Dec-2021
JP-2023084565-A Antibody or antigen-binding fragment thereof Active 07-Dec-2021
JP-2023084671-A Antibody or antigen-binding fragment thereof Active 07-Dec-2021 C07K16/18
To view Periotherapia’s complete patent history, request access »

Periotherapia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Periotherapia Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Japan Agency for Medical Research and Development Government
Techno Science Venture Capital Minority
Chishima Land Corporation Minority
Chishima Real Estate Real Estate Minority
Chushin Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Periotherapia FAQs

  • When was Periotherapia founded?

    Periotherapia was founded in 2017.

  • Where is Periotherapia headquartered?

    Periotherapia is headquartered in Osaka, Japan.

  • What is the size of Periotherapia?

    Periotherapia has 14 total employees.

  • What industry is Periotherapia in?

    Periotherapia’s primary industry is Drug Discovery.

  • Is Periotherapia a private or public company?

    Periotherapia is a Private company.

  • What is Periotherapia’s current revenue?

    The current revenue for Periotherapia is .

  • How much funding has Periotherapia raised over time?

    Periotherapia has raised $18.5M.

  • Who are Periotherapia’s investors?

    Japan Agency for Medical Research and Development, Techno Science, Chishima Land, Chishima Real Estate, and Chushin Venture Capital are 5 of 9 investors who have invested in Periotherapia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process